- NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS, CARDIOVASCULAR EFFECTS).
- ANSAID® is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS, Gastrointestinal Effects—Risk of Ulceration, Bleeding and Perforation).
(flurbiprofen tablets, USP) 50 mg and 100 mg
ANSAID Tablets contain flurbiprofen, which is a member of the phenylalkanoic acid derivative group of nonsteroidal anti-inflammatory drugs. ANSAID Tablets are white, oval, film-coated tablets for oral administration. Flurbiprofen is a racemic mixture of (+)S- and (-)R- enantiomers. Flurbiprofen is a white or slightly yellow crystalline powder. It is slightly soluble in water at pH 7.0 and readily soluble in most polar solvents.
Carefully consider the potential benefits and risks of ANSAID and other treatment options before deciding to use ANSAID. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).
ANSAID is indicated:
- For relief of the signs and symptoms of rheumatoid arthritis.
- For relief of the signs and symptoms of osteoarthritis.
Published Studies Related to Ansaid (Flurbiprofen)
Utility of the sore throat pain model in a multiple-dose assessment of the acute
analgesic flurbiprofen: a randomized controlled study. 
multiple-dose safety and efficacy of lozenges containing flurbiprofen at 8.75 mg... CONCLUSIONS: Utilizing the sore throat pain model with multiple doses over 24
Efficacy of the lidocaine/flurbiprofen axetil combination for reducing pain during the injection of propofol. [2011.07]
BACKGROUND: Pain during the injection of propofol is a common clinical problem. Lidocaine pretreatment, preceded by venous occlusion, is the most popular method for reducing pain during the injection of propofol but cannot entirely control such pain. We aimed to evaluate the efficacy of lidocaine, flurbiprofen axetil (an injectable prodrug of flurbiprofen), and the two in combination for reducing pain during the injection of propofol... CONCLUSION: The lidocaine/flurbiprofen axetil combination, compared with lidocaine 40 mg or flurbiprofen 50 mg, effectively reduces pain during the injection of propofol.
Effects of flurbiprofen on CRP, TNF-alpha, IL-6, and postoperative pain of thoracotomy. [2011.03.10]
OBJECTIVE: The aims of this study were to evaluate serum levels of acute phase reactants, such as CRP and cytokines (TNF-alpha and IL-6) in patients who have undergone thoracotomy and to investigate the effects of flurbiprofen on postoperative inflammatory response... CONCLUSIONS: Patients undergoing thoracotomy showed reduced postoperative pain, mean additional analgesic consumption, and serum IL-6 and CRP levels, when flurbiprofen was added to systemic analgesic therapy. Analgesia with anti-inflammatory drug may contribute to the attenuation of the postoperative inflammatory response and prevent postoperative pain in patients undergoing thoracotomy.
Lack of preemptive analgesia by intravenous flurbiprofen in thyroid gland surgery: a randomized, double-blind and placebo-controlled clinical trial. 
BACKGROUND: Nowadays, increasingly more preemptive analgesia studies focus on postoperative pain; however, the impact of preemptive analgesia on perioperative opioid requirement is not well defined. This study was carried out in order to evaluate whether preoperative intravenous flurbiprofen axetil can reduce perioperative opioid consumption and provide postoperative analgesia in patients undergoing thyroid gland surgery... CONCLUSION: Preoperative administration of intravenous Flurbiprofen axetil reduced analgesic consumption during surgery, but not postoperative pain scores.
Efficacy of the lidocaine/flurbiprofen axetil combination for reducing pain
during the injection of propofol. 
pain during the injection of propofol... CONCLUSION: The lidocaine/flurbiprofen axetil combination, compared with
Clinical Trials Related to Ansaid (Flurbiprofen)
Flurbiprofen Tape for Treatment of Chronic Low Back Pain [Completed]
The purpose of this trial is to evaluate the analgesic efficacy and safety of flurbiprofen
tape for chronic low back pain (lasting greater than three months.
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients [Recruiting]
To explore and compare antihyperalgesic effects of butorphanol, flurbiprofen axetil, and a
combination of both received before anesthesia induction.
To evaluate and examine the incidence of adverse effects and dose dependence with the
purpose of selecting the optimum dose.
To discover and confirm sex differences in antihyperalgesic activity of butorphanol, and
identify whether butorphanol combined with flurbiprofen axetil can reverse sex differences.
Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects [Recruiting]
For previous clinical trials, R-flurbiprofen has been prepared in tablet form. In this study
R-flurbiprofen, will be available as gelatine capsules.
This study aims to show the bioavailability of R-flurbiprofen when administered in gelatine
capsules. The serum availability will be determined by analysis of pharmakokinetic
(pK)-blood samples at different time points. To assess the safety of the administered
capsules adverse events will be documented.
Analysis of lipid signaling molecules in plasma will be done to assess the role of this
molecules as variable for therapeutic effects.
Flurbiprofen Axetil for Uterine Contraction Pain [Completed]
A Phase 1 Drug-drug Interaction Study in Healthy Volunteers [Completed]
This is an open-label, single-sequence, drug-drug interaction study in healthy male and
female subjects. There is no formal research hypothesis to be statistically tested. It is
expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may
increase the exposure of montelukast, flurbiprofen, and digoxin.
Page last updated: 2015-08-10